The elusive lives of beluga whales, shrouded by the icy expanses of the Arctic, have long presented a formidable challenge…
Read More
Unlocking the Secrets of the Arctic’s Elusive White Whales: DNA Study Reveals Surprising Mating Strategies in Bristol Bay Belugas
The intricate social tapestry and reproductive strategies of beluga whales, the Arctic’s charismatic white cetaceans, have long remained shrouded in…
Read More
The Secret Lives of Beluga Whales Unveiled: DNA Study Reveals Remarkable Mating Strategies and Genetic Resilience in Bristol Bay Population
Beluga whales, the charismatic toothed whales of the Arctic, have long held an air of mystery, their lives largely shrouded…
Read More
Arctic Secrets Unlocked: DNA Study Reveals Surprising Family Dynamics and Genetic Resilience in Bristol Bay Belugas
The enigmatic lives of beluga whales, often shrouded by the vast and icy expanses of the Arctic, are beginning to…
Read More
Arctic Enigma: DNA Unlocks Beluga Whale Family Secrets in Bristol Bay
Beluga whales, elusive inhabitants of the frigid Arctic, have long presented a profound challenge to researchers. Their lives unfold largely…
Read More
US FDA Grants Priority Review to Bristol Myers Squibb’s Camzyos for Adolescent Patients with Obstructive Hypertrophic Cardiomyopathy
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos…
Read More
Bristol Myers Squibb and Hengrui Pharma Forge Landmark $15.2 Billion Oncology and Immunology Collaboration
Bristol Myers Squibb (BMS) and Chinese biopharmaceutical giant Hengrui Pharma have announced a monumental licensing and collaboration agreement, potentially valued…
Read More
Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries
Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…
Read More
Bristol Myers Squibb and Oxford BioTherapeutics Forge Alliance to Pioneer Novel T-Cell Engager Therapies for Solid Tumors
Bristol Myers Squibb (BMS) and Oxford BioTherapeutics (OBT) have announced a significant strategic alliance aimed at discovering and developing a…
Read MoreYOU MAY HAVE MISSED
